Fedele, Carmine

SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models

Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery

Protein Tyrosine PhosphatasesMelanoma and MAPK Pathways

Cited by 315

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling

Fedele, C., Li, S., Teng, K. W., Foster, C. J. R., Peng, D., Ran, H., Mita, P., Geer, M. J., Hattori, T., Koide, A., et al. (2021) · Journal of Experimental Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 265

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 150

Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts

Trerotola, M., Ganguly, K. K., Fazli, L., Fedele, C., Lu, H., Dutta, A., Liu, Q., De Angelis, T., Riddell, L. W., Riobo, N. A., et al. (2015) · Oncotarget

Prostate Cancer Treatment and ResearchCell Adhesion Molecules Research

Cited by 70

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer

Prahallad, A., Weiss, A., Voshol, H., Kerr, G., Sprouffske, K., Yuan, T., Ruddy, D., Meistertzheim, M., Kazic-Legueux, M., Kottarathil, T., et al. (2023) · Cancer Research

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 30